Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)

NCT01472029 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT01472029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01472029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
September 12, 2016
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the gastroesophageal junction, adenocarcinoma of the stomach